Jeffrey Boone
Cardiovascular Disease · Greenwood Village, CONPI 1306010863
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 60.9% of it on its own, with 34 other manufacturers making up the rest. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 706 payments — averaging $406.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$175K
- Heartflow, Inc.$82K
- Kowa Pharmaceuticals America, Inc.$13K
- Novartis$12K
- Novo Nordisk$689
- Amarin Pharma, Inc.$464
- plus $3K from 29 others
What the payments were for
- Consulting fees$84,09029%
- Speaking & faculty fees$158,47055%
- Travel & lodging$26,0269%
- Food & beverage$13,1445%
- Education$5,0412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 366 | $174,633 |
| Heartflow, Inc. | 22 | $82,262 |
| Kowa Pharmaceuticals America, Inc. | 39 | $13,070 |
| Novartis | 87 | $12,309 |
| Novo Nordisk | 29 | $689 |
| Amarin Pharma, Inc. | 16 | $464 |
| AstraZeneca | 29 | $432 |
| Esperion Therapeutics, Inc. | 24 | $424 |
| Cleerly, Inc. | 5 | $347 |
| Boehringer Ingelheim | 14 | $285 |
| Bayer | 10 | $255 |
| Medicure Pharma Inc. | 3 | $235 |
| Lilly USA, LLC | 10 | $159 |
| Eisai Inc. | 3 | $150 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Johnson & Johnson | 5 | $108 |
| Pfizer | 5 | $104 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $92 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77 |
| Alnylam Pharmaceuticals Inc. | 2 | $68 |
| Lundbeck LLC | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Ionis Pharmaceuticals, Inc. | 1 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Abbott | 1 | $25 |
| Abiomed | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$170,358
- FFRct$81,749
- LEQVIO$10,310
- Livalo$3,323
- Seglentis$3,171
- Cleerly Ischemia$286
- Cleerly Labs$286
- Vascepa$242
- HMG-CoA reductase inhibitor.$163
- DISEASE STATE$125
- Kerendia$123
- Wegovy$121
- AIMOVIG$116
- Dayvigo$112
How this compares
$286,772 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 763 | $749,396 |
| Praluent PenAlirocumab | 134 | $130,398 |
| OzempicSemaglutide | 59 | $89,577 |
| JardianceEmpagliflozin | 74 | $77,054 |
| EliquisApixaban | 66 | $71,579 |
| FarxigaDapagliflozin Propanediol | 66 | $67,531 |
| MounjaroTirzepatide | 55 | $63,486 |
| VascepaIcosapent Ethyl | 80 | $60,271 |
| EntrestoSacubitril/Valsartan | 44 | $54,731 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $24,254 |
| NexletolBempedoic Acid | 25 | $21,140 |
| LivaloPitavastatin Calcium | 26 | $13,041 |
| Colchicine | 64 | $5,721 |
| Telmisartan | 227 | $5,618 |
| Celecoxib | 165 | $5,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $689 | $89,57759 claims |
| Boehringer IngelheimJardiance | $285 | $77,05474 claims |
| PfizerEliquis | $104 | $71,57966 claims |
| AstraZenecaFarxiga | $432 | $67,53166 claims |
| Lilly USA, LLCMounjaro | $159 | $63,48655 claims |
| NovartisEntresto | $12,309 | $54,73144 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $424 | $45,39448 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13,070 | $13,04126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Greenwood Village
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Deborah JalowiecColorado Springs$106K
- Edward GillAurora$96K
- Sameer MehtaDenver$92K
- Grant BaileyLittleton$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.